London-based LabGenius raises €11.5 million to scale its AI-driven drug discovery platform

LabGenius raises $10M to use AI for protein drug discovery

LabGenius Raises $10M in Series A Funding

LabGenius, a London-based drug discovery company, has raised €11.5 million in Series A funding led by Lux Capital and Obvious Ventures. The company uses AI, robotic automation, and synthetic biology to discover novel protein therapeutics. The funding will be used to scale the team, expand the discovery platform, and initiate an internal asset development program. LabGenius aims to develop novel antibody fragments capable of treating conditions that cannot be addressed using conventional antibody formats.

LabGenius Secures €11.5 Million Series A to Scale AI-Driven Drug Discovery Platform

LabGenius is a drug discovery company that is using artificial intelligence (AI), robotic automation, and synthetic biology to discover novel protein therapeutics. The company has developed EVA – a robot scientist capable of designing, conducting, and learning from its own experiments. The learning aspect means that EVA gets continuously smarter as it unpicks the genetic design rules that underpin life.

LabGenius is a drug discovery company using AI, robotic automation, and synthetic biology to discover novel protein therapeutics.

6 years ago

LabGenius Secures €11.5 Million Series A to Scale AI-Driven Drug Discovery Platform

ProblemBiotechnology

Solution

Covered on